Reframe Daily: Hot-flash pill passes big trial; ER STI screening works; Ebola shots safe in pregnancy

Reframe Daily—curated by Christin Chong (neuroscience PhD, Buddhist chaplain, healthtech strategy consultant)—delivers optimistic and credible healthtech updates you won’t find in most popular news outlets, from sources scientists and healthcare providers read and trust.

Today in one sentence: A non-hormone pill cut hot flashes in a big trial; a simple ER plan caught more hidden STIs in teens and young adults; a two-dose Ebola vaccine was safe and built strong antibodies in pregnant women; cancer immune drugs given around surgery for mesothelioma looked safe and trackable with a blood test; and scientists found a brain pathway that could lead to new treatments for bipolar depression.

Christin’s note: just got home with a cold/flu that stole my voice 😅 will rest up now and see how things go tomorrow! if you have any remedies for cold/flu’s please let me know 🙂

Pop in the Discord to chat about health →
https://forms.gle/tN3oabFTsDF21VnS8

Weekly personal shares from Christin here →
http://christin.substack.com/

Good news: A non-hormone pill eased hot flashes and night sweats in a large trial—offering relief without estrogen.

Elinzanetant for the Treatment of Vasomotor Symptoms Associated With Menopause: A Phase 3 Randomized Clinical Trial

Market readiness: 🙂🙂🙂🙂 (Late-stage RCT with a well-tolerated, non-hormonal drug; not yet FDA-approved but positioned for review/labeling in the US.) 

Good news: An ER trial validated a simple testing strategy to catch more hidden STIs in teens and young adults—something hospitals can adopt now.

Gonorrhea and Chlamydia Screening for Adolescents and Young Adults in Emergency Departments

Market readiness: 🙂🙂🙂🙂 (Uses standard swabs/lab tests already in US care; trial evidence supports immediate practice change while broader uptake rolls out.) 

Good news: A two-dose Ebola vaccine schedule was safe during pregnancy and built strong antibody responses in moms and babies.

Heterologous two-dose Ebola vaccine regimen in pregnant women in Rwanda: a randomized controlled phase 3 trial

Market readiness: 🙂🙂🙂 (Vaccines exist, but this pregnancy-specific evidence needs regulatory guidance before routine US use.) 

Good news: Using existing immunotherapy medicines before and after surgery for mesothelioma proved feasible and safe, and a blood test tracked residual cancer. (Cancer — single item as requested.)

Perioperative nivolumab or nivolumab plus ipilimumab in resectable diffuse pleural mesothelioma: a phase 2 trial and ctDNA analyses

Market readiness: 🙂🙂🙂 (Drugs are FDA-approved but not for this perioperative use; promising phase 2 data and ctDNA utility need phase 3 confirmation.) 

Good news: Scientists found a new brain pathway (involving the Serinc2 gene) that may drive bipolar depression—pointing to a fresh treatment target.

Microglia contribute to bipolar depression through Serinc2-dependent phospholipid synthesis

Market readiness: 🙂 (Early mechanistic biology; helpful for drug discovery but far from clinical use.)

Thank you for taking the time to take care of yourself and your loved ones.